60
Participants
Start Date
September 30, 2012
Primary Completion Date
December 23, 2016
Study Completion Date
December 23, 2016
Entecavir and peginterferon
Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 µg/1.73m2 subcutaneously once weekly for 40 weeks beginning 8 weeks after entecavir monotherapy).
Johns Hopkins University, Baltimore
University of Minnesota, Minneapolis
Saint Louis Children's Medical Center, St Louis
University of Texas Southwestern, Dallas
University of California San Francisco Medical Center, San Francisco
Seattle Children's Hospital, Seattle
Hospital of Sick Children, Toronto
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH